Lonza and Ypsomed Enter into a Collaboration for Development and Manufacturing of Patch Injector-Based Combination Products for Pharmaceutical Customers

Basel, Switzerland, 09 November 2020 – Ypsomed, a leading Swiss specialist for the development and manufacture of injection and infusion systems for self-medication, and Lonza, a leading contract development and manufacturing service provider for the pharmaceutical industry, announced today that the companies have entered into a development and manufacturing collaboration to offer comprehensive patch injector-based solutions to the pharmaceutical and biotech industry. The resulting solution aims to allow self-administration of innovative therapies to improve patient benefit and convenience.

Many patients need to receive significant numbers of injections or infusions regularly. In the future, instead of visiting a doctor or a hospital for these treatments, patients may be able to use a wearable patch injector for self-administration into subcutaneous tissue at their own homes.

Pharmaceutical and biotechnology companies interested in this technology can benefit from a reliable injection device technology platform delivered by partners with experience and capabilities in their respective fields of pharmaceutical product development and commercialization. The collaboration will provide flexibility and know-how to allow for faster and more robust development timelines to provide pharmaceutical and biotech customers with large-volume delivery options of up to 10 mL currently, for their innovative therapies.

Based on Ypsomed's prefilled, easy-to-use patch injector YpsoDose®, the companies will offer a comprehensive solution to pharmaceutical and biotech customers for easy development and commercialization of patch-injector-based therapies. Employing the 10 ml cartriQ® glass cartridge manufactured by Schott, a leading supplier of parenteral packaging to the pharmaceutical industry, Lonza's Drug Product Services (DPS) will develop drug product formulations and the filling process for customers. Lonza will fill and test cartridges and assemble, test and release the patch-injector from the components delivered by Ypsomed for patient use.

Thanks to this collaboration, customers seeking rapid access to the device for clinical trials to the commercial supply of filled, assembled, and released products using the injection devices will be able to receive an integrated contract development and manufacturing service.

About Lonza

At Lonza, we combine technological innovation with world class manufacturing and process excellence. Together, these enable our customers to deliver their discoveries in the healthcare, preservation, and protection sectors.

We are a preferred global partner to the pharmaceutical, biotech and specialty ingredients markets. We work to prevent illness and promote a healthier world by enabling our customers to deliver innovative medicines that help treat or even cure a wide range of diseases. We also offer a broad range of microbial control solutions, which help to create and maintain a healthy environment.

Founded in 1897 in the Swiss Alps, Lonza today operates in 120 sites and offices in more than 35 countries. With approximately 15,500 full-time employees, we are built from high-performing teams and of individual employees who make a meaningful difference to our own business, as well as the communities in which we operate. The company generated sales of CHF 5.9 billion in 2019 with a CORE EBITDA of CHF 1.6 billion. Find out more at and follow us on Twitter @LonzaGroup or Facebook @LonzaGroupAG.

Lonza Contact Details:

Dr. Sanna Fowler
Head of External Communications
Lonza Group Ltd
Tel 41 61 316 8929
[email protected]

Dirk Oehlers
Investor Relations
Lonza Group Ltd
Tel 41 79 421 1609

Additional Information and Disclaimer for Lonza

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise required by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.